Hartman Institute for Therapeutic Organ Regeneration

Efficient hemogenic endothelial cell specification by RUNX1 is dependent on baseline chromatin accessibility of RUNX1-regulated TGFβ target genes.

TitleEfficient hemogenic endothelial cell specification by RUNX1 is dependent on baseline chromatin accessibility of RUNX1-regulated TGFβ target genes.
Publication TypeJournal Article
Year of Publication2021
AuthorsHowell ED, Yzaguirre AD, Gao P, Lis R, He B, Lakadamyali M, Rafii S, Tan K, Speck NA
JournalGenes Dev
Volume35
Issue21-22
Pagination1475-1489
Date Published2021 Nov 01
ISSN1549-5477
KeywordsCell Differentiation, Chromatin, Core Binding Factor Alpha 2 Subunit, Fetus, Hemangioblasts, Hematopoiesis, Hematopoietic Stem Cells, Humans, Transforming Growth Factor beta, Transforming Growth Factor beta1
Abstract

<p>Hematopoietic stem and progenitor cells (HSPCs) are generated de novo in the embryo from hemogenic endothelial cells (HECs) via an endothelial-to-hematopoietic transition (EHT) that requires the transcription factor RUNX1. Ectopic expression of RUNX1 alone can efficiently promote EHT and HSPC formation from embryonic endothelial cells (ECs), but less efficiently from fetal or adult ECs. Efficiency correlated with baseline accessibility of TGFβ-related genes associated with endothelial-to-mesenchymal transition (EndoMT) and participation of AP-1 and SMAD2/3 to initiate further chromatin remodeling along with RUNX1 at these sites. Activation of TGFβ signaling improved the efficiency with which RUNX1 specified fetal ECs as HECs. Thus, the ability of RUNX1 to promote EHT depends on its ability to recruit the TGFβ signaling effectors AP-1 and SMAD2/3, which in turn is determined by the changing chromatin landscape in embryonic versus fetal ECs. This work provides insight into regulation of EndoMT and EHT that will guide reprogramming efforts for clinical applications.</p>

DOI10.1101/gad.348738.121
Alternate JournalGenes Dev
PubMed ID34675061
PubMed Central IDPMC8559682
Grant ListT32 DK007780 / DK / NIDDK NIH HHS / United States
F31 HL150952 / HL / NHLBI NIH HHS / United States
U01 HL100405 / HL / NHLBI NIH HHS / United States
R01 HL091724 / HL / NHLBI NIH HHS / United States
T32 CA009140 / CA / NCI NIH HHS / United States
R01 HD089245 / HD / NICHD NIH HHS / United States
F31 HL120615 / HL / NHLBI NIH HHS / United States
T32 HD083185 / HD / NICHD NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065